NAFLD and cardiovascular disease
Open Access
- 1 October 2018
- journal article
- Published by Wolters Kluwer Health in Porto Biomedical Journal
- Vol. 3 (2) , e2
Abstract
Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic hepatic disease and liver transplant in Western societies. The increasing prevalence is related to dietary changes and sedentarism and follows the increasing frequency of obesity and type 2 diabetes mellitus. Growing evidence of association of NAFLD with cardiovascular diseases (CVD), independent of cardiovascular risk factors, has prompted the clarification of whether the liver is mainly a key-effector or a target-organ of the metabolic disarrangements in the metabolic syndrome. The therapeutic strategies able to alter liver disease progression and, through this, reduce the cardiovascular risk have also been tested in the last 2 decades. This review focus on the possible interactions between hepatic disease, metabolic syndrome, and CVD, and on their implications for clinical practice.Keywords
This publication has 157 references indexed in Scilit:
- Genomic approaches to studying the human microbiotaNature, 2012
- Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohortJournal of Hepatology, 2012
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trialHepatology, 2011
- The Association of Genetic Variability in Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) with Histological Severity of Nonalcoholic Fatty Liver Disease†Hepatology, 2010
- A position statement on NAFLD/NASH based on the EASL 2009 special conferenceJournal of Hepatology, 2010
- Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort StudyAmerican Journal of Gastroenterology, 2010
- Increased Fructose Consumption Is Associated With Fibrosis Severity in Patients With Nonalcoholic Fatty Liver DiseaseHepatology, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling PathwayHepatology, 2010
- Long-Term Follow-Up of Patients With Nonalcoholic Fatty LiverClinical Gastroenterology and Hepatology, 2009